Clinical assessment of magnetic resonance imaging‑guided radiofrequency ablation for breast cancer

  • Authors:
    • Jian Li
    • Dan‑Dan Wang
    • Yu‑Nian Zhao
    • Jian‑Wei Zhou
    • Jin‑Hai Tang
  • View Affiliations

  • Published online on: August 2, 2019     https://doi.org/10.3892/mco.2019.1905
  • Pages: 411-415
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the efficacy of magnetic resonance imaging (MRI)‑guided radiofrequency ablation (RFA) for breast cancer patients who cannot undergo traditional surgery. A total of 10 patients were treated by MRI‑guided RFA, of whom 6 had stage IV disease (lung metastasis n=3, bone metastasis n=1, liver metastasis n=1 and mediastinal metastasis n=1) and the remaining 4 patients, who refused surgery, had stage III disease accompanied by severe underlying conditions. The changes in feasibility, tumor volume, bleeding, local recurrence, metastasis and complications were evaluated after RFA. The patients were followed up at 1, 3, 6 and 12 months, and annually thereafter. A total of 14 RFA sessions were successfully performed (100%) in the 10 patients, among whom 7 patients underwent a single RFA session, 2 patients underwent two sessions, and 1 patient underwent three sessions. Compared with pre‑RFA, the volume of the tumors at 6 months after RFA was markedly decreased. There was no local tumor recurrence or metastasis detected during a mean follow‑up period of 19.5±3.46 months, and no major complications were reported. Therefore, RFA was found to be a minimally invasive and feasible treatment method in the present study, and MRI‑guided RFA may be a promising alternative option for breast cancer patients who are unable to tolerate surgery. However, more prospective studies on the applicability of RFA in breast cancer are required.

References

1 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI

2 

Niederkorn A, Sadoghi B and Komericki P: Pulsed-dye laser therapy for carcinoma in situ of the penis. Br J Dermatol. 179:195–196. 2018. View Article : Google Scholar : PubMed/NCBI

3 

Lunardi A, Cervelli R, Volterrani D, Vitali S, Lombardo C, Lorenzoni G, Crocetti L, Bargellini I, Campani D, Pollina LE, et al: Feasibility of percutaneous intrahepatic split by microwave ablation (PISA) after portal vein embolization for hypertrophy of future liver remnant: The radiological stage-1 ALPPS. Cardiovasc Intervent Radiol. 41:789–798. 2018.PubMed/NCBI

4 

Wiksell H, Lofgren L, Schassburger KU, Grundstrom H, Janicijevic M, Lagerstedt U, Leifland K, Nybom R, Rotstein S, Saracco A, et al: Feasibility study on the treatment of small breast carcinoma using percutaneous US-guided preferential radiofrequency ablation (PRFA). Breast. 19:219–225. 2010. View Article : Google Scholar : PubMed/NCBI

5 

Haar GT and Coussios C: High intensity focused ultrasound: Physical principles and devices. Int J Hyperthermia. 23:89–104. 2007. View Article : Google Scholar : PubMed/NCBI

6 

Gazis AN, Beuing O, Franke J, Jollenbeck B and Skalej M: Bipolar radiofrequency ablation of spinal tumors: Predictability, safety and outcome. Spine J. 14:604–608. 2014. View Article : Google Scholar : PubMed/NCBI

7 

Wah TM, Sourbron S, Wilson DJ, Magee D, Gregory WM, Selby PJ and Buckley DL: Renal cell carcinoma perfusion before and after radiofrequency ablation measured with dynamic contrast enhanced MRI: A pilot study. Diagnostics (Basel). 8:E32018. View Article : Google Scholar : PubMed/NCBI

8 

Rajyaguru DJ, Borgert AJ, Smith AL, Thomes RM, Conway PD, Halfdanarson TR, Truty MJ, Kurup AN and Go RS: Radiofrequency ablation versus stereotactic body radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients: Analysis of the national cancer database. J Clin Oncol. 36:600–608. 2018. View Article : Google Scholar : PubMed/NCBI

9 

Lee SH, Jin YJ and Lee JW: Survival benefit of radiofrequency ablation for solitary (3–5 cm) hepatocellular carcinoma: An analysis for nationwide cancer registry. Medicine (Baltimore). 96:e84862017. View Article : Google Scholar : PubMed/NCBI

10 

Chen T, Jin J and Chen S: Clinical assessment of computed tomography guided radiofrequency ablation in the treatment of inoperable patients with pulmonary tumors. J Thoracic Dis. 9:5131–5142. 2017. View Article : Google Scholar

11 

Chen J, Zhang C, Li F, Xu L, Zhu H, Wang S, Liu X, Zha X, Ding Q, Ling L, et al: A meta-analysis of clinical trials assessing the effect of radiofrequency ablation for breast cancer. OncoTargets Ther. 9:1759–1766. 2016.

12 

Chen K, Zhan MX, Hu BS, Li Y, He X, Fu SR, Xin YJ and Lu LG: Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma. Oncol Lett. 15:315–323. 2018.PubMed/NCBI

13 

Bale R, Richter M, Dunser M, Levy E, Buchberger W and Schullian P: Stereotactic radiofrequency ablation for breast cancer liver metastases. J Vasc Interv Radiol. 29:262–267. 2017. View Article : Google Scholar : PubMed/NCBI

14 

Mauri G, Sconfienza LM, Pescatori LC, Fedeli MP, Ali M, Di Leo G and Sardanelli F: Technical success, technique efficacy and complications of minimally-invasive imaging-guided percutaneous ablation procedures of breast cancer: A systematic review and meta-analysis. Eur Radiol. 27:3199–3210. 2017. View Article : Google Scholar : PubMed/NCBI

15 

Nguyen T, Hattery E and Khatri VP: Radiofrequency ablation and breast cancer: A review. Gland Surg. 3:128–135. 2014.PubMed/NCBI

16 

Shah DR, Green S, Elliot A, McGahan JP and Khatri VP: Current oncologic applications of radiofrequency ablation therapies. World J Gastrointest Oncol. 5:71–80. 2013. View Article : Google Scholar : PubMed/NCBI

17 

Oura S, Tamaki T, Hirai I, Yoshimasu T, Ohta F, Nakamura R and Okamura Y: Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size. Breast Cancer. 14:48–54. 2007. View Article : Google Scholar : PubMed/NCBI

18 

Earashi M, Noguchi M, Motoyoshi A and Fujii H: Radiofrequency ablation therapy for small breast cancer followed by immediate surgical resection or delayed mammotome excision. Breast Cancer. 14:39–47. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Yamamoto N, Fujimoto H, Nakamura R, Arai M, Yoshii A, Kaji S and Itami M: Pilot study of radiofrequency ablation therapy without surgical excision for T1 breast cancer: Evaluation with MRI and vacuum-assisted core needle biopsy and safety management. Breast Cancer. 18:3–9. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Hua YQ, Wang P, Zhu XY, Shen YH, Wang K, Shi WD, Lin JH, Meng ZQ, Chen Z and Chen H: Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy. Pancreatology. 17:967–973. 2017. View Article : Google Scholar : PubMed/NCBI

21 

Li P, Xiao-Yin T, Cui D, Chi JC, Wang Z, Wang T, Qi XX and Zhai B: Evaluation of the safety and efficacy of percutaneous radiofrequency ablation for treating multiple breast fibroadenoma. J Cancer Res Ther. 12 (Suppl):C138–C142. 2016. View Article : Google Scholar : PubMed/NCBI

22 

Wang H, Liu B, Long H, Zhang F, Wang S and Li F: Clinical study of radiofrequency ablation combined with TACE in the treatment of breast cancer with liver metastasis. Oncol Lett. 14:2699–2702. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Chiu HY, Leu JD, Chang CY, Lee YJ and Chen WR: Combination of radiofrequency ablation and glycated chitosan as treatment on a syngeneic breast tumor model. Anticancer Res. 37:2965–2974. 2017.PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 11 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, J., Wang, D., Zhao, Y., Zhou, J., & Tang, J. (2019). Clinical assessment of magnetic resonance imaging‑guided radiofrequency ablation for breast cancer. Molecular and Clinical Oncology, 11, 411-415. https://doi.org/10.3892/mco.2019.1905
MLA
Li, J., Wang, D., Zhao, Y., Zhou, J., Tang, J."Clinical assessment of magnetic resonance imaging‑guided radiofrequency ablation for breast cancer". Molecular and Clinical Oncology 11.4 (2019): 411-415.
Chicago
Li, J., Wang, D., Zhao, Y., Zhou, J., Tang, J."Clinical assessment of magnetic resonance imaging‑guided radiofrequency ablation for breast cancer". Molecular and Clinical Oncology 11, no. 4 (2019): 411-415. https://doi.org/10.3892/mco.2019.1905